Neuroblastic tumours are composed of variable proportions of neuroblasts and Schwann cells. Whether both components share a common neoplastic origin is highly debated and discrepant results have been reported about the presence of tumour-related genetic alterations in Schwann cells. We have used X-methylation analysis and array-CGH to investigate contiguous Schwannian and neuroblastic areas in tumours with a nodular pattern. A skewed X inactivation was observed in four out of five stromal components. Interestingly, in these four cases, the X-inactivation profiles of the neuroblastic components were identical to the matched stromal areas. However, whereas all neuroblastic areas displayed chromosomal imbalances, no alteration was found in any Schwann cell components. Similarly, no alteration was observed in a series of 19 tumours with a single stroma-rich component, which occasionally exhibited a skewed X-inactivation pattern (3/17 informative tumours). Altogether, this indicates that most stroma-rich tumours display a polyclonal proliferation and that Schwann cells do not derive from neuroblasts. However, in tumours with both stroma-rich and -poor components, our results suggest that cells from both areas share a common progenitor.
Peripheral neuroblastic tumours constitute a heterogeneous group of tumours arising from the adrenal gland or the sympathetic nervous system of children. They are composed of two main cell populations, the neuroblastic component with sympathetic neuronal features and the stromal component with Schwann cell characteristics. The relative abundance of each cell subtype splits the peripheral neuroblastic tumours into two categories: (1) stroma-rich-tumours, composed of highly predominant proliferations of Schwann cells with scattered neuroblastic cells, frequently differentiated and (2) stroma-poor tumours, harbouring a high amount of neuroblastic cells, frequently poorly differentiated, with very few Schwann cells. The latter tumours, termed neuroblastomas, harbour a high aggressiveness and a poor differentiation, whereas the former, ganglioneuromas or ganglioneuroblastomas, are benign or low-malignant tumours. Finally, some neuroblastic tumours harbour a nodular pattern (ganglioneuroblastoma, nodular) characterized by the presence of a neuroblastomatous stroma-poor component well circumcised in a stroma-rich environing tissue (Peuchmaur et al., 2003) .
Some observations led to the hypothesis that Schwann cells derive from neuroblasts. Indeed, a higher abundance of Schwann cells is observed in more differentiating tumours and neuroblastomas may, either spontaneously or under treatment, evolve towards ganglioneuromas (Rangecroft et al., 1978; Haas et al., 1988; Nishihira et al., 2000) . Moreover, Schwann cells have been observed in distant bone metastases of neuroblastomas (Bhattacharyya et al., 1999) . This hypothesis of Schwann cells deriving from neuroblasts is also supported by observations that neuroblastoma cells acquire 'Schwann cell-like' features upon in vitro incubation with differentiating cocktails (Sugimoto et al., 1988) . Finally, common chromosomal alterations have been described in the matched neuroblastic and Schwannian components of some neuroblastic tumours (Mora et al., 2001; Coco et al., 2005) . On the opposite, Ambros et al. (1996) failed to detect in Schwann cells any of the genetic alterations observed in the contiguous neuroblastic cells. These results have led to the hypothesis of Schwann cells not being of tumoural origin but rather proliferating in response to signals emitted by maturing neuroblasts (Ambros et al., 2001) . Accordingly, the graft of human neuroblastoma cell lines in mouse sciatic nerve resulted in a high proliferation of Schwann cells and, concomitantly, led to the maturation of the neuroblastic cells (Liu et al., 2005) . Hence, the neoplastic or reactive nature of Schwann cells remains controversial.
The clonal origin of a tissue can be surveyed through two main kinds of markers: (1) somatic genetic alterations and (2) chromosome X-inactivation pattern. In females indeed, each X chromosome may be inactivated through a random methylation process early in embryogenesis. Once established in a particular cell, the methylation pattern is invariably transmitted to all the progenies. Hence, a unique non-random pattern of methylation is expected in malignant tumours, since all cells are supposed to derive from the same precursor. Such a skewed X-inactivation pattern has therefore been widely used as a clonality marker in tumours. However, this approach has presently not been used for the analysis of neuroblastic tumours. To address the issue of the relationship between schwannian and neuroblastic components, we investigated the X-inactivation pattern in tumours composed of two very clear contiguous but distinct proliferations, one made of Schwann cells and the other made of neuroblasts (Figure 1) . A total of 12 tumours were selected from female patients. The neuroblastic stroma-poor nodule and the stroma-rich component were first identified by a screening on paraffin-embedded tissue. Corresponding frozen sections were stained with hematoxylin eosin safran and reviewed to identify the two territories. Six tumours finally provided frozen material from both regions. Microscopic examination allowed drawing the borders of the neuroblastic nodules and the subsequent straightforward, eye-controlled macro-dissection. The size of macro-dissected samples approximately ranged from 10 to 20 mm 2 . X-inactivation pattern was studied through the human androgen receptor assay (HUMARA) after sodium bisulphite treatment. Five out of six tumours displayed informative heterozygosity. Skewed methylation patterns, defined by the predominant amplification of distinct alleles with primers specific for the methylated and unmethylated sequences, were observed in all informative neuroblastic nodules ( Figure 2 ). This was indicative of the expected clonal nature of these neoplastic nodules. More surprisingly, a similar skewed pattern was observed in the corresponding stroma-rich components of four out of five cases, the last case exhibiting a random methylation profile (Figure 2 ; Supplementary Figure 1 ). Very interestingly, in all four cases, the methylated and unmethylated alleles were identical in the Schwann cell and neuroblastic components ( Figure 2 ). This observation could suggest that one of the components derives from the other. To test this hypothesis, we used array-CGH to investigate tumourrelated somatic rearrangements. As expected, all neuroblastic areas harboured chromosomal alterations usually observed in neuroblastoma, including segmental imbalances on chromosome 17q, 11q and/or 1p, whole chromosome gains and losses and MYCN amplification in one case ( Figure 3 ; Table 1 ). Interestingly, in two cases, two distant neuroblastic nodules could be studied. In each case, array-CGH demonstrated a similar pattern of alterations with nevertheless slight differences between distinct nodules from the same tumour (see chromosomes 1 and 19 in Figure 4 ). This indicated that distant nodules share a common origin even though they may have acquired few divergent alterations. In contrast to the neuroblastic components, the Schwann cell areas harboured flat profiles. Knowing that (1) the tumour and stromal areas were very clearly defined and therefore easily macrodissected, (2) array CGH results of the stromal components were completely flat, for instance for the 17q or 2p loci strongly altered in the tumour components and (3) a loss-of-heterozygosity analysis is very sensitive to the presence of normal cells-reciprocally it can be inferred that a high number of tumour DNA is required to alter a heterozygous pattern (Merlo et al., 1991) . We conclude that skewed methylation is truly due to a monoclonal pattern of Schwann cells in nodular tumours and not due to a contamination by neuroblasts.
Given the high frequency of a skewed X-methylation pattern in stroma-predominant areas of nodular tumours, we then addressed the question of this feature being a general characteristic of stroma-rich tumours. We selected 19 stroma-rich tumours (12 ganglioneuromas and 7 intermixed ganglioneuroblastomas) from female patients. Among 17 informative tumours, three ganglioneuromas (18%) revealed a skewed X-methylation, two being informative at both HUMARA and PGK1 loci, and one at the PGK1 locus only ( Supplementary  Figures 3 and 4) . The 14 (82%) other cases showed a random X-inactivation profile. In addition, array-CGH analysis of these stroma-rich tumours did not evidence any alteration. These results show that stroma-rich tumours do not harbour detectable genetic alteration and usually present a polyclonal X-inactivation pattern.
The skewed X-methylation profile observed in a subset of stroma-rich tumours could theoretically reflect a pseudoclonal methylation pattern related to a somatic selection after X-chromosome inactivation. Such selection mechanisms have been described in female carriers of various X-linked disorders (for review see Chen and Prchal, 2007) . Alternatively, a skewed X methylation could result from a non-malignant monoclonality, such as those observed in smooth muscle cells in atheroma or Relationship between neuroblasts and Schwann cells F Bourdeaut et al in lymphocytes expansion after a specific antigenic stimulation. We also cannot exclude that the observed clonal pattern, relatively rare in ganglioneuromas and intermixed ganglioneuroblastomas as compared to nodular ganglioneuroblastomas, results from a stochastic skewing early in embryogenesis. The variable X-methylation patterns may also reflect a true heterogeneity. In this hypothesis, it will remain to be studied on larger group of tumours whether the monoclonal profile is associated with a more aggressive evolution pattern. Finally, it may also be hypothesized that, in some cases, monoclonal stroma-rich tumours may constitute nodular ganglioneuroblastoma whose neuroblastic nodule(s) escaped detection.
Figure 2 X-methylation pattern of stroma-rich and neuroblastic regions. DNAs were extracted by classical phenol-chloroform procedures from sections of frozen tumour material after eye-controlled macro-dissections. X-methylation pattern was studied after sodium bisulphite treatment and HUMARA assay. The assay involves a chemical conversion of unmethylated cytosines to uracil then a PCR amplification with primers specific for methylated or unmethylated alleles. A total of 1.5 mg DNA was denatured with 0.3 M NaOH and treated with 0.75 mM hydroquinone and 1.6 M sodium Bisulphite overnight at 55 1C. DNA was then purified with the QIAquick gel extraction kit. PCR amplification of the modified HUMARA exon1 was performed with 5 0 -labelled primers (6FAM) as described elsewhere (Kubota et al., 1999) . PCR products were separated on an automated DNA sequencer and analysed with the Genotyper software. D, size difference between both alleles (in bp); NB, neuroblastic nodule; SC, Schwann cell component; M, PCR amplification results with primers specific for the methylated sequence; UM, PCR amplification results with primers specific for the unmethylated sequence. Figure 3 Chromosomal imbalances in neuroblastic nodules but not in Schwann cell components. Array-CGH were performed as described by Idbaih et al. (2005) . Arrays were scanned with a 4000B Axon Scan (Axon). Image analysis was performed with Genepix 5.1 software (Axon) and Cy5/Cy3 ratio signals were measured. Gains were defined by a Cy5/Cy3 ratio >1.2 (in red) and losses by a Cy5/Cy3 ratio o0.8 (in green). Normalization and data analyses were performed with the VAMP software developed by the Bioinformatic Department of the Curie Institute (La Rosa et al., 2006) . Chromosomal imbalances were restricted to the neuroblastic component (NB); in particular, loss of 11q and gain of 17q in case no. 2, MYCN amplification in case no. 6. No alteration was detected in the Schwann cell component (SC). The profiles of both nodules show an apparent imbalance of the X chromosome (see Figure 4 knowing that the competitor is a male DNA). In fact, analysis of the HUMARA locus shows a heterozygosity indicating that this tumour has two copies of chromosome X within a pseudo-triploid DNA content. Methylation status analysis shows that cells have kept one methylated and one unmethylated X chromosome. The partial loss of one X chromosome in the nodule results in a loss-ofheterozygosity at the HUMARA locus which is therefore not informative to investigate the methylation pattern (Supplementary Figure 1) .
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e One nodule harbours a chromosome X imbalance (see Figure 4 knowing that the competitor is a male DNA), whereas the other nodule exhibits a normal XX profile. In that case, the HUMARA locus is homozygous therefore precluding the investigation of the methylation pattern (Supplementary Figure 2) .
A major observation is that the stroma-rich and -poor areas of nodular tumours harbour identical X-inactivation profiles. We propose that the most likely hypothesis to account for these results is that the schwannian and neuroblastic proliferations are derived from a common ancestor. This hypothesis is consistent with the proposed common neural crest origin of neuroblasts and Schwann cells. Indeed, Dupin et al. (1990) showed that in vitro cultures of a single neural crest cell can lead to both adrenergic neurons and Schwann cells, indicating that migrating neural crests contain pluripotent precursors among which 'glial-neuronal (GN) progenitors' have both glial and neuronal potentials. One of the hypotheses accounting for the common clonal X-inactivation pattern between Schwann cells and neuroblasts may be that the whole sympathetic ganglia derive from a single progenitor. Such clonal expansions from single precursor cells are responsible for the 'patch' organization of some epithelial tissues (Tsai et al., 1996; Jovanovic et al., 2003; Novelli et al., 2003) . Although we cannot completely rule out this hypothesis since we could not test the X-inactivation pattern of normal ganglia, the polyclonal pattern presently observed in most stromarich tumours argues against the assumption of sympathetic organs deriving from a single cell. Hence, the identical X-methylation pattern of stromal and neuroblastic components in nodular tumours is rather related to a pathological proliferation than to a physiological organogenesis.
A major difference between the neuroblastic and Schwann cell components is the lack of detectable genetic alteration in the latter. This may indicate that the neuroblastic and schwannian components are clonally derived from distinct GN progenitors with the same X-inactivation pattern. However it seems rather unlikely that two unrelated clonal proliferations have occurred independently within the same tissue. This would also not explain the origin of a monoclonal schwannian component. Moreover, the statistics indicate that the overall probability of a coincidence (that is, two independent proliferations sharing identical Relationship between neuroblasts and Schwann cells F Bourdeaut et al X-inactivation pattern in four different cases) is rather low (P ¼ 1/16). A more likely hypothesis is that neuroblastic and schwannian components are derived from a common preneoplastic progenitor (see a proposed model in Figure 5 ). Following this hypothesis, oncogenesis of nodular neuroblastoma may occur in two subsequent steps. In the first step, a premalignant progenitor, without detectable genetic alteration, may acquire selective advantage over normal progenitors and still retain the ability to differentiate into the neuronal and schwannian lineages. The role of occult genetic mutations or of heritable epigenetic changes in this premalignant stage would remain to be investigated. Second, the occurrence of additional changes in the neuronal lineage, including chromosomal gains or losses, may lead to malignant transformation. Such progression models from a premalignant proliferation with retained pluripotency to a single-lineage malignancy have been described in various myeloproliferative disorders (review in Raskind et al., 1998) . Altogether, our results suggest the existence of an early pre-oncogenic event occurring in a GN progenitor in some nodular neuroblastic tumours. Whether this progression model only applies to nodular tumours or can be extended to other types of neuroblastoma requires further investigation. Discrepant results have been observed concerning the genetic status of neuroblastic and Schwann cell components in stroma-rich and -poor tumours (Ambros et al., 1996; Mora et al., 2001) . We believe that our results help to clarify the debate showing that, at least in the model studied here, stromal cells do not derive from neuroblastic cells, but that nevertheless both cell populations likely share a common progenitor, therefore putting this past controversy into new genetic and cellular perspectives.
